AstraZeneca announced update on the safety of COVID-19 vaccine
On Apr. 14, 2021, following concern raised around thrombotic events, AstraZeneca offered its reassurance on the safety of…
Moderna announced clinical progress from mRNA Vaccine
On Apr. 14, 2021, Moderna announced that results from a preclinical study of the Companyï¾’s COVID-19 variant-specific vaccine…
Novavax announced participation in University of Oxford Com-COV2 study comparing mixed COVID-19 vaccine combinations
On Apr. 14, 2021, Novavax announced its participation in an expanded investigator-initiated Phase 2 clinical trial called Comparing…
NIAID trial of Anti-CD14 antibody to treat COVID-19 respiratory disease began
On Apr. 13, 2021, a clinical trial testing the safety and efficacy of an investigational monoclonal antibody for…
Positive topline data showed Fostamatinib met primary endpoint of safety in phase 2 clinical trial in hospitalized COVID-19 patients
On Apr. 13, 2021, Rigel Pharma announced the completion of patient enrollment in a multi-center Phase 2 clinical…
Moderna updated clinical and supply on COVID-19 vaccine program
On Apr. 13, 2021, Moderna announced that new results from a preclinical study of the Companyï¾’s COVID-19 variant-specific…
Health Canada Issued Resverlogix authorization to begin immediate clinical studies of apabetalone for COVID-19
On Apr. 12, 2021, Resverlogix announced that it had successfully received its desired ﾓNo Objection Letterï¾” from Health…
Phase III trial showed subcutaneous administration of investigational antibody cocktail reduced risk of symptomatic COVID-19 infections by 81%
On Apr. 12, 2021, Roche confirmed positive results from the phase III REGN-COV 2069 trial assessing the ability…
Asthma drug budesonide shortened recovery time in non-hospitalised patients with COVID-19
On Apr. 12, 2021, Oxford University reported that early treatment with inhaled budesonide shortened recovery time by a…
FDA authorized new high-throughput, automated system for leading COVID-19 test
On Apr. 12, 2021, Thermo Fisher Scientific announced that the U.S. Food and Drug Administration (FDA) had granted…
Biotechnology | COVID-19 | Life Science News | NIH | Therapeutics | Vaccine
NIH COVID-19 treatment guidelines strongly recommended Use of REGEN-COV in high risk outpatients
On Apr. 9, 2021, Regeneron announced that newly updated National Institutes of Health (NIH) COVID-19 treatment guidelines strongly…
Pfizer and BioNTech requested regulatory agencies expand Emergency Use of COVID-19 vaccine to adolescents
On Apr. 9, 2021, Pfizer announced they had requested amendments to the U.S. Emergency Use Authorization (EUA) of…
Antiviral drug Favipiravir investigated as a possible COVID-19 treatment for at-home recovery in PRINCIPLE trial
On Apr. 8, 2021, Oxford University announced that favipiravir was to be investigated in the UK as part…
ImmunityBio announced single prime hAd5 COVID-19 vaccination induced 10-fold increase in T cell response
On Apr. 8, 2021, ImmunityBio reported initial data indicating that a single subcutaneous injection of the companyï¾’s COVID-19…
NIH began study of allergic reactions to Moderna, Pfizer-BioNTech COVID-19 vaccines
On Apr. 7, 2021, the NIH announced that a clinical trial was underway to determine whether people who…
WHO Global Advisory Committee on Vaccine Safety reported on AstraZeneca COVID-19 vaccine
On Apr. 7, 2021, the COVID-19 subcommittee of the WHO Global Advisory Committee on Vaccine Safety (GACVS) announed…
AIM ImmunoTech announced positive data in phase 1 study Investigating intranasal administration of Ampligen as potential treatment for COVID-19
On Apr. 7, 2021, AIM ImmunoTech announced that it had completed dosing of Cohort 1 in a Phase…
Moderna announced publication of antibody persistence data of its COVID-19 vaccine in the NEJM
On Apr. 7, 2021, Moderna announced publication of antibody persistence data out to 6 months following the second…
CDC awarded $3 billion to expand COVID-19 vaccine programs
On Apr. 7, 2021, the Centers for Disease Control and Prevention (CDC) announced it had awarded $3 billion…
Moderna and Catalent announced long-term strategic collaboration for vial filling of COVID-19 vaccine
On Apr. 6, 2021, Moderna and Catalent announced the expansion of their strategic collaboration to dedicate a new…
Nearly 80 percent of teachers, school staff, and childcare workers received at least one shot of COVID-19 vaccine
On Apr. 6, 2021, the Centers for Disease Control and Prevention (CDC) reported that nearly 80 percent of…
The FDA issued an EUA to Symbiotica for the COVID-19 self-collected antibody test system
On Apr. 5, 2021, the FDA issued an Emergency Use Authorization (EUA) to Symbiotica for the COVID-19 Self-Collected…
Positive phase 1/2 results reported for Valneva’s inactivated COVID-19 vaccine candidate using CpG 1018ï¾™ adjuvant
On Apr. 5, 2021, Dynavax Technologies announced that Valneva had reported positive initial results for Part A of…
Innovation Pharma announced increased dosing in phase 2 clinical trial of Brilacidin in COVID-19 patients
On Apr. 5, 2021, Innovation Pharmaceuticals announced that an independent Data Monitoring Committee (DMC) completed its scheduled review…
Novavax initiated COVID-19 vaccine clinical trial crossover
On Apr. 5, 2021, Novavax announced the initiation of crossover arms in two ongoing clinical trials of NVX-CoV2373,…
Emergent announced support of manufacturing capacity expansion for Johnson & Johnson’s COVID-19 vaccine
On Apr. 4, 2021, Emergent BioSolutions announced it had received a contract modification to increase the original task…
Emergent announced topline data from NIAID phase 3 ITAC Trial evaluating immunoglobulins as treatment for patients with COVID-19
On Apr. 2, 2021, Emergent BioSolutions announced that topline data from the ITAC trial had demonstrated that the…
FDA revised Moderna COVID-19 vaccine EUA to increase the number of vaccine doses available
On Apr. 1, 2021, the FDA announced two revisions regarding the number of doses per vial available for…
Moderna provided storage update and FDA authorization for 15-doses per vial of COVID-19 vaccine
On Apr. 1, 2021, Moderna announced that based on submitted stability data, the U.S. Food and Drug Administration…
Pfizer and BioNTech confirmed high efficacy and no serious safety concerns in updated COVID-19 vaccine study
On Apr. 1, 2021, Pfizer and BioNTech announced updated topline results from analysis of 927 confirmed symptomatic cases…